Tirzepatide
vs
Retatrutide (GLP-3)
Side-by-side comparison of mechanism, research, dosing, side effects, and pricing.
Tirzepatide
Dual receptor agonist. Outperforms semaglutide in head-to-head trials.
Retatrutide (GLP-3)
Next-generation triple receptor agonist. Phase 3 clinical research underway.
Research base
FDA approved. Phase 3 trials show superior metabolic effects vs single-receptor agonists.
Phase 2 human trials demonstrate exceptional metabolic effects. 99%+ purity verified across batches in research-grade product.
How they work
Activates both GLP-1 and GIP receptors. Dual-pathway stimulation.
Simultaneously activates GLP-1, GIP, and glucagon receptors. Triple-receptor synergy for metabolic optimization.
Protocols compared
What to expect
Common: GI adjustment. Well-tolerated overall.
Effects within 2-4 weeks
Common: GI adjustment, appetite reduction (intended effect). Well-tolerated in clinical trials.
Effects observed within 2-4 weeks; full metabolic adaptation 12+ weeks
Price comparison
The honest verdict
Pick Tirzepatide if: Highly effective alone. Dual-agonist mechanism is its key feature.
Pick Retatrutide (GLP-3) if: Highly effective standalone compound. Triple-receptor agonism is its primary differentiator.
Why not both? Some researchers run them together. Check our Interaction Matrix to see if these compounds synergize or work independently.
